Pharmacology and clinical trials of reversibly-binding P2Y12 inhibitors

被引：35
作者：
Storey, Robert F. [1 ]
机构：
[1] Univ Sheffield, Dept Cardiovasc Sci, Sheffield S10 2RX, S Yorkshire, England
来源：
THROMBOSIS AND HAEMOSTASIS | 2011年 / 105卷
关键词：
ADP receptors; antiplatelet agents; arterial thrombosis; platelet pharmacology; antiplatelet drugs; ACUTE CORONARY SYNDROMES; ELEVATION MYOCARDIAL-INFARCTION; RECEPTOR ANTAGONIST; PLATELET-AGGREGATION; DOUBLE-BLIND; CLOPIDOGREL RESPONSIVENESS; ADENOSINE-DIPHOSPHATE; ANTIPLATELET THERAPY; THROMBUS STABILITY; ACTIVE METABOLITE;
D O I：
10.1160/THS10-12-0769
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The important role of the P2Y(12) receptor in amplification of platelet activation and associated responses and the limitations associated with clopidogrel therapy have led to the development of novel inhibitors of this receptor. Three reversibly-binding P2Y(12) inhibitors are in phase 3 development, ticagrelor, cangrelor and elinogrel. The pharmacology and clinical trial data for each of these inhibitors are discussed and compared with relevant data for the thienopyridines clopidogrel and prasugrel.
引用
收藏
页码：S75 / S81
页数：7
相关论文
共 65 条
  • [21] Randomized Double-Blind Assessment of the ONSET and OFFSET of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease The ONSET/OFFSET Study
    Gurbel, Paul A.
    Bliden, Kevin P.
    Butler, Kathleen
    Tantry, Udaya S.
    Gesheff, Tania
    Wei, Cheryl
    Teng, Renli
    Antonino, Mark J.
    Patil, Shankar B.
    Karunakaran, Arun
    Kereiakes, Dean J.
    Parris, Cordel
    Purdy, Drew
    Wilson, Vance
    Ledley, Gary S.
    Storey, Robert F.
    [J]. CIRCULATION, 2009, 120 (25) : 2577 - U103
  • [22] Platelet Inhibition with Cangrelor in Patients Undergoing PCI.
    Harrington, Robert A.
    Stone, Gregg W.
    McNulty, Steven
    White, Harvey D.
    Lincoff, A. Michael
    Gibson, C. Michael
    Pollack, Charles V., Jr.
    Montalescot, Gilles
    Mahaffey, Kenneth W.
    Kleiman, Neal S.
    Goodman, Shaun G.
    Amine, Maged
    Angiolillo, Dominick J.
    Becker, Richard C.
    Chew, Derek P.
    French, William J.
    Leisch, Franz
    Parikh, Keyur H.
    Skerjanec, Simona
    Bhatt, Deepak L.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (24) : 2318 - 2329
  • [23] The P2Y1 receptor, necessary but not sufficient to support full ADP-induced platelet aggregation, is not the target of the drug clopidogrel
    Hechler, B
    Eckly, A
    Ohlmann, P
    Cazenave, JP
    Gachet, C
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1998, 103 (03) : 858 - 866
  • [24] The P2Y1 receptor is necessary for adenosine 5′-diphosphate-induced platelet aggregation
    Hechler, B
    Léon, C
    Vial, C
    Vigne, P
    Frelin, C
    Cazenave, JP
    Gachet, C
    [J]. BLOOD, 1998, 92 (01) : 152 - 159
  • [25] HELD C, 2011, J AM COLL C IN PRESS
  • [26] Cytochrorne P4502C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects
    Hulot, Jean-Sebastien
    Bura, Alessandra
    Villard, Eric
    Azizi, Michel
    Remones, Veronique
    Goyenvalle, Catherine
    Aiach, Martine
    Lechat, Philippe
    Gaussem, Pascale
    [J]. BLOOD, 2006, 108 (07) : 2244 - 2247
  • [27] Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis:: a double-blind comparison to clopidogrel with aspirin
    Husted, S
    Emanuelsson, H
    Heptinstall, S
    Sandset, PM
    Wickens, M
    Peters, G
    [J]. EUROPEAN HEART JOURNAL, 2006, 27 (09) : 1038 - 1047
  • [28] Antagonists of the platelet P2T receptor:: A novel approach to antithrombotic therapy
    Ingall, AH
    Dixon, J
    Bailey, A
    Coombs, ME
    Cox, D
    McInally, JI
    Hunt, SF
    Kindon, ND
    Teobald, BJ
    Willis, PA
    Humphries, RG
    Leff, P
    Clegg, JA
    Smith, JA
    Tomlinson, W
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (02) : 213 - 220
  • [29] James S, 2010, EUR HEART J
  • [30] Ticagrelor Versus Clopidogrel in Acute Coronary Syndromes in Relation to Renal Function Results From the Platelet Inhibition and Patient Outcomes (PLATO) Trial
    James, Stefan
    Budaj, Andrzej
    Aylward, Philip
    Buck, Kristen K.
    Cannon, Christopher P.
    Cornel, Jan H.
    Harrington, Robert A.
    Horrow, Jay
    Katus, Hugo
    Keltai, Matyas
    Lewis, Basil S.
    Parikh, Keyur
    Storey, Robert F.
    Szummer, Karolina
    Wojdyla, Daniel
    Wallentin, Lars
    [J]. CIRCULATION, 2010, 122 (11) : 1056 - 1067
1234567